2020
DOI: 10.1002/acg2.102
|View full text |Cite
|
Sign up to set email alerts
|

Use of thrombopoietin receptor agonists after hematopoietic progenitor cell transplantation

Abstract: Hematopoietic stem cell transplant (HCT) is used with increasing frequency for the treatment of malignant and nonmalignant diseases. Thrombocytopenia is a common complication following HCT and is associated with decreased survival. Supportive care with platelet transfusion requires significant resources, reduces quality of life, and is associated with several adverse effects including transfusion reaction, infection, and alloimmunization. Thrombopoeitin receptor agonists (TPO-RA) have been found to be safe and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 82 publications
(278 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?